Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Haiming Chen

Showing results (241-250 of 270) with videos related to

Pageof 27
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 3, 2025
Targeting Fibroblast Activation Protein for Molecular Imaging of Fibrotic Remodeling in Pulmonary Arterial HypertensionPeng Hou, Haiming Chen, Sihao Liang, et al.
Frontiers in Pharmacology|February 7, 2022
The Gene Expression Analysis of Peripheral Blood Monocytes From Psoriasis Vulgaris Patients With Different Traditional Chinese Medicine SyndromesYue Lu, Yao Qi, Li Li, et al.
Hematological Oncology|August 31, 2022
The JAK1/2 inhibitor ruxolitinib downregulates the immune checkpoint protein B7H3 in multiple myelomaNing Xu, Erin Yu, Nicole Ng, et al.
International Journal of Oncology|June 28, 2014
Overexpression of Yin Yang 1 in bone marrow-derived human multiple myeloma and its clinical significanceSara Huerta-Yepez, Hong Liu, Stavroula Baritaki, et al.
European Radiology|June 4, 2024
The diagnostic value of [<sup>18</sup>F]FAPI-42 PET/CT for pulmonary artery masses: comparison with [<sup>18</sup>F]FDG PET/CTPeng Hou, Kaixiang Zhong, Wenliang Guo, et al.
International Journal of Oncology|May 11, 2006
LAGlambda-1: a clinically relevant drug resistant human multiple myeloma tumor murine model that enables rapid evaluation of treatments for multiple myelomaRichard A Campbell, Steven J Manyak, Honghao H Yang, et al.
Annals of Hematology|January 13, 2019
The anti-myeloma effects of the selective JAK1 inhibitor (INCB052793) alone and in combination in vitro and in vivoEric Sanchez, Mingjie Li, Saurabh Patil, et al.
British Journal of Haematology|May 10, 2006
Serum pleiotrophin levels are elevated in multiple myeloma patients and correlate with disease statusHoward S Yeh, Haiming Chen, Steven J Manyak, et al.
British Journal of Haematology|April 23, 2020
Estimating a normal reference range for serum B-cell maturation antigen levels for multiple myeloma patientsScott Jew, Sean Bujarski, Camilia Soof, et al.
Drug Design, Development and Therapy|June 19, 2024
The Benefit of the Optimized Formula of Yinxieling in Psoriasis Vulgaris via Regulation on Autophagy Based on microRNA Expression Profile and Network Pharmacology AnalysisYue Lu, Simin Pan, Wenzhen Li, et al.
Pageof 27

Showing results (241-250 of 270) with videos related to

Sort By:
Pageof 27
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 3, 2025
Targeting Fibroblast Activation Protein for Molecular Imaging of Fibrotic Remodeling in Pulmonary Arterial HypertensionPeng Hou, Haiming Chen, Sihao Liang, et al.
Frontiers in Pharmacology|February 7, 2022
The Gene Expression Analysis of Peripheral Blood Monocytes From Psoriasis Vulgaris Patients With Different Traditional Chinese Medicine SyndromesYue Lu, Yao Qi, Li Li, et al.
Hematological Oncology|August 31, 2022
The JAK1/2 inhibitor ruxolitinib downregulates the immune checkpoint protein B7H3 in multiple myelomaNing Xu, Erin Yu, Nicole Ng, et al.
International Journal of Oncology|June 28, 2014
Overexpression of Yin Yang 1 in bone marrow-derived human multiple myeloma and its clinical significanceSara Huerta-Yepez, Hong Liu, Stavroula Baritaki, et al.
European Radiology|June 4, 2024
The diagnostic value of [<sup>18</sup>F]FAPI-42 PET/CT for pulmonary artery masses: comparison with [<sup>18</sup>F]FDG PET/CTPeng Hou, Kaixiang Zhong, Wenliang Guo, et al.
International Journal of Oncology|May 11, 2006
LAGlambda-1: a clinically relevant drug resistant human multiple myeloma tumor murine model that enables rapid evaluation of treatments for multiple myelomaRichard A Campbell, Steven J Manyak, Honghao H Yang, et al.
Annals of Hematology|January 13, 2019
The anti-myeloma effects of the selective JAK1 inhibitor (INCB052793) alone and in combination in vitro and in vivoEric Sanchez, Mingjie Li, Saurabh Patil, et al.
British Journal of Haematology|May 10, 2006
Serum pleiotrophin levels are elevated in multiple myeloma patients and correlate with disease statusHoward S Yeh, Haiming Chen, Steven J Manyak, et al.
British Journal of Haematology|April 23, 2020
Estimating a normal reference range for serum B-cell maturation antigen levels for multiple myeloma patientsScott Jew, Sean Bujarski, Camilia Soof, et al.
Drug Design, Development and Therapy|June 19, 2024
The Benefit of the Optimized Formula of Yinxieling in Psoriasis Vulgaris via Regulation on Autophagy Based on microRNA Expression Profile and Network Pharmacology AnalysisYue Lu, Simin Pan, Wenzhen Li, et al.
Pageof 27